Sessa Capital’s Moderna MRNA Stock Holding History

Sessa Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-743,081	Closed	-$21.9M	–	38
2025 Q4	$21.9M	Hold	743,081	–	–	0.41%	24
2025 Q3	$19.2M	Hold	743,081	–	–	0.45%	22
2025 Q2	$20.5M	Hold	743,081	–	–	0.6%	20
2025 Q1	$21.1M	Buy	+743,081	New	+$26.4M	0.82%	22

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sessa Capital's MRNA Position: Q1 2026 in Review

Sessa Capital sold out of Moderna (MRNA) in Q1 2026, closing a stake of 743,081 shares — an estimated $21.9M sold.

Sessa Capital first reported a position in MRNA in Q1 2025 and held it in 4 quarters. The position peaked at $21.9M in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Sessa Capital reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Sessa Capital sold 743,081 Moderna shares in Q1 2026, an estimated $21.9M.
Sessa Capital first reported a position in Moderna in Q1 2025 and held it in 4 quarters.
Sessa Capital's Moderna position peaked at $21.9M in Q4 2025.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Sessa Capital's 13F filing for Q1 2026, filed 15 May 2026.